Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06307925 | A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 122 | HC Biopharma Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06968572 | Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 245 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06304571 | A Study of HC006 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 76 | HC Biopharma Inc.INDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT06954558 | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor(GUARDIAN) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06907628 | A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05749432 | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05473624 | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06927349 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06094556 | An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 240 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06096974 | Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | recruiting | Phase 1 | 60 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06710379 | A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | recruiting | Phase 1 | 68 | Adcentrx TherapeuticsINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05544240 | Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 20 | Williams Cancer FoundationOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05477849 | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors | recruiting | Phase 1 | 30 | Shanghai Virogin Biotech Co., Ltd.INDUSTRY | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT06716619 | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 32 | Guangzhou FineImmune Biotechnology Co., LTD.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06897228 | PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | recruiting | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05970016 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 56 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05828459 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | recruiting | Phase 1 | 150 | Onward TherapeuticsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05142423 | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06707610 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors | recruiting | Phase 1 | 234 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 2 | Mar 12, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06730386 | A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 100 | AkesoINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06443489 | A Trial of SHR-4849 in Advanced Solid Tumors | recruiting | Phase 1 | 80 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT03943004 | Trial of DFP-14927 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06173219 | Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 38 | China-Japan Friendship HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 95 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06464055 | A Study of GQ1010 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06801470 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CD-001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 137 | CD (Suzhou) Biopharma Co., Ltd.OTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04872166 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | recruiting | Phase 1 | 112 | Edgewood Oncology Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy(IXACT) | recruiting | Phase 1 / Phase 2 | 18 | Psivac LtdINDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06038396 | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05205850 | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 135 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05789602 | A Study of BPI-460372 in Advanced Solid Tumor Patients | recruiting | Phase 1 | 82 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06016062 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 221 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06764628 | A Study of SHR-4375 in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2025source: clinicaltrials